Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

2.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

3.

Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Jacob RA, Moyo T, Schomaker M, Abrahams F, Grau Pujol B, Dorfman JR.

J Virol. 2015 May;89(10):5264-75. doi: 10.1128/JVI.00129-15. Epub 2015 Feb 11.

4.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

5.

HIV vaccine design and the neutralizing antibody problem.

Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT.

Nat Immunol. 2004 Mar;5(3):233-6. No abstract available.

PMID:
14985706
7.

Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.

Andrabi R, Kumar R, Bala M, Nair A, Biswas A, Wig N, Kumar P, Pal R, Sinha S, Luthra K.

Virol J. 2012 Sep 12;9:196. doi: 10.1186/1743-422X-9-196.

8.

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR.

Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.

9.

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.

J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.

10.

Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

Bouvin-Pley M, Morgand M, Meyer L, Goujard C, Moreau A, Mouquet H, Nussenzweig M, Pace C, Ho D, Bjorkman PJ, Baty D, Chames P, Pancera M, Kwong PD, Poignard P, Barin F, Braibant M.

J Virol. 2014 Dec;88(23):13910-7. doi: 10.1128/JVI.02083-14. Epub 2014 Sep 17.

11.

Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.

Pinter A.

Curr HIV Res. 2007 Nov;5(6):542-53. Review.

PMID:
18045110
12.

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.

Mouquet H, Klein F, Scheid JF, Warncke M, Pietzsch J, Oliveira TY, Velinzon K, Seaman MS, Nussenzweig MC.

PLoS One. 2011;6(9):e24078. doi: 10.1371/journal.pone.0024078. Epub 2011 Sep 8.

13.

Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.

Shmelkov E, Krachmarov C, Grigoryan AV, Pinter A, Statnikov A, Cardozo T.

PLoS One. 2014 Feb 25;9(2):e89987. doi: 10.1371/journal.pone.0089987. eCollection 2014.

14.

Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, Kitchin D, Botha G, Gorman J, Garrett NJ, Abdool Karim SS, Shapiro L, Williamson C, Kwong PD, Mascola JR, Morris L, Moore PL.

Nat Med. 2015 Nov;21(11):1332-6. doi: 10.1038/nm.3963. Epub 2015 Oct 12.

15.

GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.

PMID:
16551265
16.

Broad neutralization coverage of HIV by multiple highly potent antibodies.

Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD; Protocol G Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P.

Nature. 2011 Sep 22;477(7365):466-70. doi: 10.1038/nature10373.

17.

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.

Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, Montefiori DC.

J Virol. 2002 Mar;76(5):2233-44.

18.

Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.

Shmelkov E, Nadas A, Swetnam J, Zolla-Pazner S, Cardozo T.

PLoS One. 2011;6(11):e27279. doi: 10.1371/journal.pone.0027279. Epub 2011 Nov 4.

19.

Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.

Trott M, Wei╬▓ S, Antoni S, Koch J, von Briesen H, Hust M, Dietrich U.

PLoS One. 2014 May 14;9(5):e97478. doi: 10.1371/journal.pone.0097478. eCollection 2014. Erratum in: PLoS One. 2014;9(8):e107089.

20.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk